Reardon Andrew, CLO, SECY, reported an open-market or private sale at LIGAND PHARMACEUTICALS INC involving 385.000000 shares for an estimated $110697.24. Reported holdings after the transaction were 36914.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
CLO & Secretary
The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $283.4300 to $284.1550. The Reporting Person undertakes to provide th…
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $284.7500 to $285.7000. The Reporting Person undertakes to provide th…
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $285.8000 to $286.7700. The Reporting Person undertakes to provide th…
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $287.0500 to $287.6600. The Reporting Person undertakes to provide th…
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $288.5500 to $289.4300. The Reporting Person undertakes to provide th…
0 other filings
0 recent txs